MYCN and metastatic neoplasm: A number of studies have shown that in patients less than 18 months of age with metastatic disease, hyperdiploidy in combination with a non-amplified MYCN gene, and a lack of specific SCAs (such as 11q deletion) is commonly predictive of a favorable outcome (10, 11, 35).